Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
3.160
-0.180 (-5.39%)
At close: May 16, 2025, 4:00 PM
3.120
-0.040 (-1.27%)
After-hours: May 16, 2025, 5:16 PM EDT
Sintx Technologies Revenue
Sintx Technologies had revenue of $369.00K in the quarter ending March 31, 2025, a decrease of -46.29%. This brings the company's revenue in the last twelve months to $2.57M, down -7.42% year-over-year. In the year 2024, Sintx Technologies had annual revenue of $2.89M with 9.90% growth.
Revenue (ttm)
$2.57M
Revenue Growth
-7.42%
P/S Ratio
1.51
Revenue / Employee
$128,450
Employees
20
Market Cap
7.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SINT News
- 1 day ago - SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization - GlobeNewsWire
- 2 months ago - SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 3 months ago - SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market - GlobeNewsWire
- 3 months ago - SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial - GlobeNewsWire
- 6 months ago - SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment - GlobeNewsWire
- 6 months ago - SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewsWire
- 6 months ago - SINTX Technologies Announces Stock Repurchase Program - GlobeNewsWire
- 6 months ago - SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 - GlobeNewsWire